The risk of early death beyond 12 years of age related to teenage pregnancies and gestational age.
Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer
SAN FRANCISCO — Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab (Tecentriq) to standard first-line chemotherapy significantly improved survival for patients with advanced esophageal